Automation has become one of the most discussed topics in pharmaceutical regulatory affairs. And for good reason. The volume of regulatory documentation continues to grow. Health authorities are raising their standards for submission quality. And regulatory teams are expected to do more with limited resources.

But automation is not a universal solution. There are situations where automating your regulatory submission process makes clear sense, and there are situations where a more cautious approach is warranted.

This article provides a practical framework for deciding when to automate, when to wait, and how to approach the transition in a way that serves your organization’s goals.

The Case for Automating Regulatory Submissions

Let us start with the scenarios where automation delivers the most value.

High-volume, repetitive submissions. If your organization regularly submits similar types of applications, such as generic drug submissions or product variations across multiple markets, automation can dramatically reduce the time and effort required. These submissions follow predictable patterns, making them ideal candidates for template-based automation and AI-assisted document assembly.

eCTD formatting and validation. The eCTD standard is precise and unforgiving. Manual formatting of eCTD documents is time-consuming and error-prone. Automating eCTD packaging, validation, and lifecycle management is one of the highest-value applications of regulatory automation. The technical nature of these tasks makes them well-suited for software, while the consequences of formatting errors make manual approaches risky.

Our article on why automation is key in regulatory submissions explores this topic in greater depth.

Data entry and form population. Every time a human manually transfers data from one system to another, there is a chance of error. Automating the population of regulatory forms using structured data from your existing systems eliminates transcription errors and speeds up the process significantly.

Cross-referencing and compliance checks. Regulatory submissions must comply with specific requirements that vary by product type, jurisdiction, and submission category. AI-powered tools can cross-reference your documents against these requirements faster and more consistently than manual review.

Deadline-driven environments. When your team is under pressure to meet tight submission deadlines, automation reduces the time spent on mechanical tasks and frees your team to focus on content quality and strategic decisions.

When Automation Works Best

Beyond the specific use cases above, there are organizational conditions that make automation more likely to succeed.

You have well-documented processes. Automation works best when the processes being automated are well understood and consistently followed. If your team already has standard operating procedures for submissions, automating those workflows is relatively straightforward.

Your data is structured and accessible. Automation tools need clean, structured data to work effectively. If your product data, clinical data, and regulatory records are stored in organized systems, automation can pull from those sources reliably. If your data is scattered across spreadsheets, emails, and individual hard drives, you may need to address data management before automation will be effective.

Our guide on pharma data management discusses how to build the data foundation that supports effective automation.

Your team is ready for the change. Automation changes workflows. Even when the change is positive, it requires adjustment. Organizations where the regulatory team is engaged in the selection and implementation process tend to have much smoother transitions than those where automation is imposed from the top down.

You have a clear understanding of your pain points. The most successful automation implementations start with a specific problem, not a general desire to “be more automated.” Identifying exactly where your process is slow, error-prone, or resource-intensive allows you to target automation where it will have the greatest impact.

When Not to Automate (or When to Wait)

Automation is not always the right answer, at least not right away. Here are situations where a more cautious approach makes sense.

First-of-its-kind submissions. If your company is preparing a novel drug application for a product category you have never submitted before, the submission process involves significant judgment and nuance. Novel submissions often require regulatory specialists to interpret guidelines, make strategic decisions about content organization, and engage directly with regulatory authorities. These are tasks that require human expertise and are not yet suitable for automation.

Unstable or unclear processes. If your team does not have a consistent process for submissions, automating what you have will only automate the inconsistency. Before investing in automation, take the time to standardize your workflows. Document your processes, identify best practices, and establish clear roles and responsibilities.

Poor data quality. Automation is only as good as the data it works with. If your product data, clinical records, or regulatory documents are incomplete, inconsistent, or poorly organized, automating the submission process will simply propagate those problems faster. Address your data quality issues first.

Small submission volumes. If your organization submits only a handful of regulatory applications per year, the return on investment for a full automation platform may not justify the cost and implementation effort. In these cases, targeted improvements to specific pain points, rather than comprehensive automation, may be more appropriate.

Regulatory uncertainty. If you are operating in a regulatory environment where requirements are actively changing or unclear, automating to current standards carries the risk that your automation will need significant rework when requirements are finalized. In these situations, maintaining flexibility through manual or semi-automated processes may be more practical.

The Hybrid Approach: Partial Automation

For most organizations, the answer is not “fully automated” or “fully manual.” The most effective approach is a hybrid model where certain tasks are automated while others remain under direct human control.

This hybrid approach typically looks like this:

• Automate: eCTD formatting, data entry, form population, validation checks, document assembly for standard submission types
• Keep manual: Strategic content decisions, novel regulatory interpretations, agency correspondence, first-in-class submissions, final review and sign-off

The key is to automate the mechanical, repetitive tasks that consume time and introduce errors, while preserving human judgment for the decisions that require expertise and context.

This is the approach that RoboReg takes. The platform handles the tasks that software does better than humans, such as data transfer, formatting, validation, and pattern matching, while keeping regulatory professionals in control of the decisions that require their expertise.

How to Evaluate Your Readiness for Automation

If you are considering automating your regulatory submission process, start with an honest assessment of your current state. Here is a practical framework:

Map your current workflow. Document every step of your submission process, from initial data gathering through final submission. Include the tools, people, and time involved at each step.

Identify your bottlenecks. Where does your process slow down? Where do errors most frequently occur? Where does your team spend the most time on tasks that do not require their expertise?

Assess your data maturity. Is your regulatory data stored in structured systems? Is it clean, complete, and consistent? If not, what would it take to get it there?

Evaluate your team’s readiness. Is your team open to changing their workflow? Do they have the capacity to participate in implementation and training?

Define your success criteria. What does successful automation look like for your organization? Faster submission timelines? Fewer rejection notices? Reduced manual effort? Be specific about what you are trying to achieve.

The Cost of Doing Nothing

While it is important to be thoughtful about when and how to automate, it is equally important to recognize the cost of maintaining the status quo.

Manual regulatory processes are not free. They consume your team’s time, introduce preventable errors, and limit your ability to scale. The pharmaceutical companies that are moving fastest to market are the ones that have found the right balance between human expertise and technological efficiency.

The regulatory outsourcing market continues to grow precisely because manual internal processes cannot keep up with increasing regulatory complexity. Automation, implemented thoughtfully, offers a way to reclaim control of your submission process.

Taking the First Step

If your assessment suggests that automation is the right move, start with the areas where you have the highest confidence in your data quality and process consistency. Build success in those areas first, then expand.

For companies looking to understand the regulatory software landscape in Canada, our complete guide to regulatory compliance software provides a thorough overview of available options and evaluation criteria.

And if you want to see how automation works in practice for Health Canada submissions, RoboReg offers a consultative approach that starts with understanding your specific needs before recommending a solution. The goal is not to automate everything. It is to automate the right things, at the right time, in the right way.